Scholarlink

<p>High-dose methotrexate(HD-MTX) has been used in clinical treatment of hematological malignancies and toxicity appeared at the same time. Gene polymorphisms may participate in the activity of MTX-related enzymes and induce drug-related toxicity. The influence of MTHFR C677T, MTHFR A1298C and ABCB1 C3435T polymorphisms on the MTX-related toxicity and delay elimination in adult with hematological malignancies is controversial. Here, a total of 111 patients were analyzed. MTHFR C677T, MTHFR A1298C and ABCB1 C3435T gene polymorphisms are related to MTX-related toxicity in adults with hematological malignancies. Age(≥ 60 years) and MTHFR 1298AC were identified as independent risk factors for delayed elimination of MTX. This reminds us that the MTHFR C677T, MTHFR A1298C and ABCB1 C3435T gene polymorphisms are expected to be a useful tool in reducing toxicity and improving outcome in personalized HD-MTX therapy for patients with hematological malignancies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MTHFR and ABCB1 polymorphisms associated with toxicity in hematological malignancies patients receiving high dose methotrexate

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月17日

查看全文
  • Yaling Shi,
  • Nan Zhou,
  • Lu Cao,
  • Dan Zhang,
  • Peng Zhang,
  • Hui Wang

摘要

High-dose methotrexate(HD-MTX) has been used in clinical treatment of hematological malignancies and toxicity appeared at the same time. Gene polymorphisms may participate in the activity of MTX-related enzymes and induce drug-related toxicity. The influence of MTHFR C677T, MTHFR A1298C and ABCB1 C3435T polymorphisms on the MTX-related toxicity and delay elimination in adult with hematological malignancies is controversial. Here, a total of 111 patients were analyzed. MTHFR C677T, MTHFR A1298C and ABCB1 C3435T gene polymorphisms are related to MTX-related toxicity in adults with hematological malignancies. Age(≥ 60 years) and MTHFR 1298AC were identified as independent risk factors for delayed elimination of MTX. This reminds us that the MTHFR C677T, MTHFR A1298C and ABCB1 C3435T gene polymorphisms are expected to be a useful tool in reducing toxicity and improving outcome in personalized HD-MTX therapy for patients with hematological malignancies.